Dogwood Therapeutics, Inc. (identified in this filing as Virios Therapeutics, Inc.) — Form 10-Q summary
Reporting period: Quarter and nine months ended September 30, 2023. The filing was signed November 13, 2023. The registrant name in the supplied filing is Virios Therapeutics, Inc.; investors should verify the issuer and filing identity.
Business context and financial results
Virios is a pre-revenue, development-stage biotechnology company developing combination antiviral candidates, principally IMC-1 for fibromyalgia and IMC-2 for Long-COVID symptoms. It reported no revenue for the three- or nine-month periods.
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $374,200 | $1,622,374 | $1,429,757 | $6,797,914 |
| General and administrative | $900,089 | $969,946 | $2,879,036 | $3,427,679 |
| Total operating expenses | $1,274,289 | $2,592,320 | $4,308,793 | $10,225,593 |
| Net loss | $1,235,074 | $2,575,715 | $4,192,842 | $10,203,278 |
| Basic and diluted loss per share | $0.06 | $0.28 | $0.23 | $1.18 |
Cash and liquidity: Cash was $4.79 million at September 30, 2023, down from $7.03 million at December 31, 2022. Nine-month operating cash use was $3.40 million; financing provided $1.16 million, primarily from an at-the-market (ATM) stock sale. Current liabilities were $487,144, and total liabilities were also $487,144. The company reported no debt outstanding. No profit margin is meaningful because the company had no revenue and incurred losses.
Equity: Stockholders’ equity was $4.76 million, versus $7.33 million at year-end 2022. Common shares outstanding were 19,257,937 at September 30; the filing reports 19,257,937 shares outstanding as of November 9, 2023.
Material changes versus prior periods
- Nine-month net loss narrowed to $4.19 million from $10.20 million, while operating cash use fell to $3.40 million from $8.80 million. Management attributed lower expenses mainly to reduced clinical-trial spending and related development activity; these reductions do not represent revenue growth.
- Q3 operating expenses declined 51% year over year, mainly because research and development expense decreased by about $1.25 million.
- The company sold 641,873 shares through its ATM program for approximately $1.36 million gross and $1.16 million net. Sales were halted in August, and the agreement was terminated effective September 28, 2023.
- During 2023, 478,625 warrants were exercised cashlessly; 285,674 shares were issued and 192,951 shares were surrendered to cover the exercise price.
Outlook, developments, and risks
- Going concern and funding: Management said cash was insufficient to fund operations and capital needs for at least 12 months and that additional capital would be needed within nine months. The filing states there is substantial doubt about the company’s ability to continue as a going concern. Financing may require equity, debt, collaboration, licensing, or other arrangements; availability and terms are uncertain, and equity financing would dilute shareholders. Failure to raise funds could delay development plans.
- IMC-1: The Phase 2b FORTRESS study did not meet its prespecified primary endpoint (p=0.302). A post-hoc analysis found statistically significant pain improvement among “new” fibromyalgia trial patients. The FDA indicated in August 2023 that chronic toxicology studies appeared adequate to support the proposed chronic-use dose. Subject to financing and FDA review, the company planned a pharmacokinetic/food-effect study and intended to begin enrollment in its first Phase 3 fibromyalgia study in mid-2024.
- IMC-2 / Long-COVID: The company reported positive findings from a 14-week, open-label exploratory study of valacyclovir plus celecoxib in female Long-COVID patients compared with a matched routine-care cohort. It planned to discuss an IND with the FDA and fund a randomized, double-blind, placebo-controlled investigator-sponsored study; enrollment was expected in Q4 2023, with results projected for the second half of 2024. These are company-reported early findings, not confirmatory trial results.
- Nasdaq listing: A November 2, 2023 notice said the stock had closed below Nasdaq’s $1.00 minimum bid-price requirement for 30 consecutive business days. The company had until April 30, 2024 to regain compliance, subject to Nasdaq rules.
- Other risks and disclosures: The company noted reliance on additional financing and third-party research organizations, clinical and regulatory uncertainty, and potential volatility in capital markets. It reported no material pending litigation, no off-balance-sheet arrangements, and effective disclosure controls as of quarter-end. The filing identifies related-party payments to a consulting firm whose managing member is the company’s Chief Medical Officer.
Most important facts for investors to verify
- Confirm that this Virios Therapeutics filing is the intended issuer and relates to Dogwood Therapeutics.
- Review subsequent financing, cash runway, and any updates to the going-concern assessment.
- Check the status of IMC-1 FDA discussions, the pharmacokinetic study, and Phase 3 timing and funding.
- Verify the design, enrollment, and results of the controlled Long-COVID study; distinguish it from the earlier open-label findings.
- Check Nasdaq bid-price compliance and any effect of future equity issuance or warrant exercises on share count and dilution.